{
    "organizations": [],
    "uuid": "4666d5eeb214f80cc4dc80abb8b672bd3fbe9e3a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-zogenix-announces-receipt-of-fda-b/brief-zogenix-announces-receipt-of-fda-breakthrough-therapy-designation-for-zx008-idUSASB0C478",
    "ord_in_thread": 0,
    "title": "BRIEF-Zogenix Announces Receipt Of FDA Breakthrough Therapy Designation For ZX008",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 6, 2018 / 1:05 PM / Updated 14 minutes ago BRIEF-Zogenix Announces Receipt Of FDA Breakthrough Therapy Designation For ZX008 Reuters Staff \nFeb 6 (Reuters) - Zogenix Inc: \n* ZOGENIX ANNOUNCES RECEIPT OF FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZX008 IN DRAVET SYNDROME \n* ZOGENIX INC - FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZX008 IS BASED ON RESULTS FROM STUDY 1 Source text for Eikon: Further company coverage:",
    "published": "2018-02-06T15:05:00.000+02:00",
    "crawled": "2018-02-06T15:27:12.046+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "receipt",
        "fda",
        "breakthrough",
        "therapy",
        "designation",
        "zx008",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "zogenix",
        "inc",
        "zogenix",
        "announces",
        "receipt",
        "fda",
        "breakthrough",
        "therapy",
        "designation",
        "zx008",
        "dravet",
        "syndrome",
        "zogenix",
        "inc",
        "fda",
        "breakthrough",
        "therapy",
        "designation",
        "zx008",
        "based",
        "result",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}